Pages that link to "Q22001442"
Jump to navigation
Jump to search
The following pages link to Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis (Q22001442):
Displaying 50 items.
- KIT proto-oncogene, receptor tyrosine kinase (Q909409) (← links)
- Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cells (Q24313261) (← links)
- One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes (Q24685763) (← links)
- c-kit Mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlation (Q24685927) (← links)
- Current approach to cutaneous mastocytosis in childhood (Q28073836) (← links)
- Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis (Q28080034) (← links)
- Signal transduction-associated and cell activation-linked antigens expressed in human mast cells (Q28202019) (← links)
- Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis (Q28344714) (← links)
- Hotspot mutations in KIT receptor differentially modulate its allosterically coupled conformational dynamics: impact on activation and drug sensitivity (Q28541374) (← links)
- Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth (Q28828739) (← links)
- Characterization of a novel human mast cell line that responds to stem cell factor and expresses functional FcεRI (Q30428097) (← links)
- Treatment of systemic mastocytosis (Q30822114) (← links)
- Detection of c-kit point mutation Asp-816 --> Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia. (Q30859697) (← links)
- Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL. (Q30914592) (← links)
- A case of 'smouldering' mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val (Q33146408) (← links)
- Mastocytosis (Q33163541) (← links)
- STI571: a magic bullet? (Q33182459) (← links)
- Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis (Q33208353) (← links)
- Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors (Q33238296) (← links)
- Phenotypic and genotypic characteristics of mastocytosis according to the age of onset (Q33327689) (← links)
- The structural insights of stem cell factor receptor (c-Kit) interaction with tyrosine phosphatase-2 (Shp-2): an in silico analysis (Q33537429) (← links)
- Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis (Q33753094) (← links)
- Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer. (Q33840864) (← links)
- RTK mutations and human syndromeswhen good receptors turn bad. (Q33927296) (← links)
- Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis (Q33948611) (← links)
- Diagnostic criteria and classification of mastocytosis: a consensus proposal (Q33948617) (← links)
- Kit signal transduction (Q33979008) (← links)
- Mastocytosis and the skin (Q33979014) (← links)
- Pediatric mastocytosis (Q33979043) (← links)
- New approaches to therapy for mastocytosis. A case for treatment with kit kinase inhibitors (Q33979068) (← links)
- Clinical and biologic diversity of leukemias occurring in patients with mastocytosis. (Q34066643) (← links)
- Mastocytosis: recent advances in defining the disease (Q34216451) (← links)
- Clinical and histopathological aspects of cutaneous mastocytosis (Q34264289) (← links)
- Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. (Q34264299) (← links)
- Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis (Q34264308) (← links)
- Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy (Q34264313) (← links)
- Mastocytosis: molecular mechanisms and clinical disease heterogeneity. (Q34264319) (← links)
- Treatment of mastocytosis: pharmacologic basis and current concepts (Q34264323) (← links)
- Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. (Q34293285) (← links)
- Cutaneous mastocytosis associated with a mixed germ cell tumour of the ovary: report of a case and review of the literature (Q34352682) (← links)
- A possible mechanism of mast cell proliferation in mastocytosis (Q34523898) (← links)
- Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial (Q34539049) (← links)
- Class III receptor tyrosine kinases: role in leukaemogenesis (Q34557003) (← links)
- Mastocytosis and disorders of mast cell proliferation (Q34613773) (← links)
- Recent advances in the understanding of mastocytosis: the role of KIT mutations. (Q34635424) (← links)
- Mastocytosis: state of the art. (Q34641105) (← links)
- Receptor tyrosine kinase mutations in myeloid neoplasms (Q34655403) (← links)
- Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease (Q34658532) (← links)
- Hematopoietic stem-cell transplantation for advanced systemic mastocytosis (Q34664111) (← links)
- Specific analysis of KIT and PDGFR-alpha expression and mutational status in Merkel cell carcinoma (Q34690237) (← links)